n (%) | |
---|---|
Patient data | |
Age (years; range) | 66 (47–84) |
Total number | 61 (100%) |
Benign prostatic hyperplasia (BPH) | 15 (24.6%) |
Low-risk PC (D’Amico) | 16 (26.2%) |
Intermediate PC (D’Amico) | 16 (26.2%) |
High-risk PC (D’Amico) | 14 (23.0%) |
PSA | |
< 4 ng/ml | 2 (3.3%) |
4-10 ng/ml | 36 (59.0%) |
10-20 ng/ml | 12 (19.7%) |
> 20 ng/ml | 5 (8.2%) |
n/a | 6 (9.8%) |
ISUP (Gleason-Score) | |
1 (6) | 17 (27.9%) |
2 (7a) | 14 (23.0%) |
3 (7b) | 1 (1.6%) |
4 (8) | 3 (4.9%) |
5 (9–10) | 11 (18.0%) |
No cancer | 15 (24.6%) |
T-stage | |
pT2a | 7 (11.5%) |
pT2b | 1 (1.6%) |
pT2c | 28 (45.9%) |
pT3/4 | 10 (16.4%) |
No cancer | 15 (24.6%) |